Ask ten people about GLP-1 side effects and you'll get ten different stories — one person who couldn't keep water down, another who barely noticed anything, and several who heard something alarming on TikTok. Anecdotes aren't data. Clinical trials are.
This is a comparison of pooled adverse event rates from the major registration trials of semaglutide (STEP 1–5, SELECT) and tirzepatide (SURMOUNT 1–4). Same methodology, same regulatory-grade reporting, different drugs. Here's what the numbers actually show.
The Core GI Side Effects: Nausea, Vomiting, Diarrhea
Gastrointestinal side effects are the most common adverse events for both drug classes. They're directly related to the mechanism of action — slowed gastric emptying is how the drugs work, and GI disruption is the cost of that mechanism.
| Side Effect | Semaglutide 2.4mg (STEP) | Tirzepatide 15mg (SURMOUNT) | Placebo (averaged) |
|---|---|---|---|
| Nausea | ~44% | ~31% | ~16% |
| Diarrhea | ~30% | ~23% | ~16% |
| Vomiting | ~24% | ~13% | ~6% |
| Constipation | ~24% | ~11% | ~6% |
| Discontinuation due to AEs | ~7% | ~6% | ~3% |
Semaglutide at the highest approved weight-loss dose (2.4 mg) has meaningfully higher rates of nausea and vomiting than tirzepatide at its highest dose (15 mg). This is consistent across trials and consistent with the pharmacology — semaglutide is a pure GLP-1 agonist, while tirzepatide's dual GLP-1/GIP mechanism may buffer GI effects through the GIP pathway.
Severity and Duration Context
Raw incidence rates don't tell the whole story. In both STEP and SURMOUNT trials, the majority of GI adverse events were classified as mild to moderate. Severe events — defined as events that interfered with daily activities or required medical intervention — occurred in roughly 3–5% of patients on active drug across both classes.
Timing matters too. GI side effects are overwhelmingly concentrated in the dose-escalation phase. Most patients experience the worst of their nausea during the first 2–4 weeks after each dose increase, with symptoms subsiding as the body adapts. By maintenance dose, the majority of patients report minimal ongoing GI disturbance.
Discontinuation rates due to adverse events — the ultimate measure of tolerability — are remarkably similar between the two drugs: approximately 6–7% for active drug versus 3% for placebo. In practical terms, the vast majority of patients who start either medication tolerate it well enough to continue.
Beyond the GI Tract
Gallbladder Events
Both semaglutide and tirzepatide carry elevated rates of cholelithiasis (gallstones) and cholecystitis. Rapid weight loss itself is a risk factor for gallstone formation, independent of the medication mechanism. Rates across trials run approximately 1.5–2.5% for active drug versus 0.5–1% for placebo. The risk is real but low, and it's a weight-loss risk, not purely a drug risk.
Pancreatitis
Acute pancreatitis has been reported in clinical trials of both drugs at very low rates — typically under 0.5%. Both drugs carry labeling warnings about pancreatitis risk, and both are contraindicated in patients with a history of pancreatitis. The signal is consistent but small across both drug classes.
Injection Site Reactions
Injection site reactions (redness, swelling, itching) occur in approximately 3–5% of patients on injectable formulations of both drugs. These are almost universally mild and transient.
What the Comparison Means for Your Decision
If your primary concern is GI tolerability, tirzepatide has an edge in the clinical data — lower rates of nausea and vomiting at comparable efficacy. If your primary concern is cardiovascular benefit, semaglutide has the SELECT trial data behind it — a 20% reduction in major adverse cardiovascular events, which tirzepatide doesn't yet have.
Neither drug is categorically "safer" than the other. Both are well-tolerated by the majority of patients, both have similar discontinuation rates, and both carry the same class-level warnings about thyroid tumors, pancreatitis, and gallbladder events.
The choice between them should be made with your prescriber, based on your specific health profile, your tolerance for GI side effects, your insurance coverage, and your treatment goals — not based on someone's Reddit post about their first week.
Many comparison sites cherry-pick a single trial's numbers to make one drug look definitively better. The reality is that trial populations, inclusion criteria, and dose-escalation schedules differ across STEP and SURMOUNT, making direct numerical comparison imperfect. The ranges above represent pooled estimates across multiple trials within each program, which is the most honest way to present the data.
Injectable semaglutide only. Physician-led, fast onboarding, custom metabolic report. HSA/FSA accepted.
Sema $99/mo, tirz $133/mo. LegitScript, 503A+503B pharmacies. Free consult, free shipping, no membership. Code x7X72r saves $25.
Injectable, oral tirzepatide, microdose. LegitScript. Flat pricing at every dose — no jumps. Commitment plans from $49/mo.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All medications require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved. Individual results vary.